REG - Lazard Asset Mgmnt Xeris Pharmaceutical - Form 8.3 - Xeris Pharmaceuticals, Inc

LazardAnnouncement

06/10/2021 15:45

RNS Number : 2445O
  
Lazard Asset Management
  
06 October 2021
  
 

 
 
FORM 8.3
 
IRISH TAKEOVER PANEL
 
DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013
 
DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
 
1.       KEY INFORMATION
 



Name of person dealing (Note 1)


 Lazard Asset Management Ltd




Company dealt in


 XERIS PHARMACEUTICALS INC




Class of relevant security to which the dealings being disclosed relate (Note 2)


 Ordinary shares  




Date of dealing


 05 October 2021



 
2.         INTERESTS AND SHORT POSITIONS
 
(a)        Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)







           Long


Short








Number






(%)


Number






(%)




(1) Relevant securities


147,719          0.222%


 2,540,688     3.82%




(2) Derivatives (other than options)












(3) Options and agreements to purchase/sell












Total


 147,719          0.222%


 2,540,688     3.82%












 
(b)        Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)



Class of relevant security:


Long


Short








Number






(%)


Number






(%)




(1) Relevant securities












 
(2) Derivatives (other than options)












 
(3) Options and agreements to purchase/sell












Total
























 
 
1.       DEALINGS (Note 4)
 
(a)      Purchases and sales
 



 
Purchase/sale


 
Number of relevant securities


 
Price per unit (Note 5)

















 
 
 
(b)      Derivatives transactions (other than options transactions)
 



Product name,
e.g. CFD


Nature of transaction
(Note 6)


Number of relevant securities
(Note 7)


Price per unit
(Note 5)




CFD


Buy to Cover


95600


USD 2.3434
 
 



 
 
(c)      Options transactions in respect of existing relevant securities
 
 
(i)       Writing, selling, purchasing or varying
 



Product name,
e.g. call option


Writing, selling, purchasing, varying etc.


Number of securities to which the option relates (Note 7)


Exercise price


Type, e.g. American, European etc.


Expiry date


Option money paid/received per unit (Note 5)

































 
 
 
(ii)      Exercising
 



Product name,
e.g. call option


Number of securities


Exercise price per unit (Note 5)

















 
 
(d)      Other dealings (including transactions in respect of new securities) (Note 4)
 



Nature of transaction
(Note 8)


Details


Price per unit
(if applicable) (Note 5)

















 
                  




 
2.       OTHER INFORMATION
 
Agreements, arrangements or understandings relating to options or derivatives
 
 
 
 
Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.
 
 
 
 
 
 
 
 
 
 
Is a Supplemental Form 8 attached? (Note 9)                                            NO
 



Date of disclosure


06 October 2021




Contact name


Harrison Leney 




Telephone number


020 7448 2335




If a connected EFM, name of offeree/offeror with which connected








If a connected EFM, state nature of connection (Note 10)







 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
  END
 
 
ISEDZMGGFVGGMZM